Abstract:Over the past two decades, many pre-clinical and clinical studies have been conducted to establish stem cell therapy as a potential treatment for heart failure. Although the original purpose was to replace the scar lesion with new cardiomyocytes generated from stem cells, there is growing evidence that therapeutic benefits may be derived mostly from cardioprotective paracrine factors released by stem cells. Paracrine factors from several cell sources, including bone marrow-derived cells, endothelial cells, and mesenchymal stromal cells, have been shown to stimulate growth of new blood vessels and activate the endogenous repair pathway in the myocardium. Several studies hypothesized that these paracrine effects work through extracellular vesicles (EVs) secreted from stem cells. EVs, including exosomes and microvesicles, are released by different types of cells and involved in both physiological and pathophysiological processes. EVs are believed to mediate intercellular communication by transmitting information from the cells of origin to their target cells. Thus, attempts are being made to utilize EVs as novel tools for various therapeutic approaches such as antitumour and regenerative therapies, and some antitumour EVs have already entered phase II human clinical trials. Since the discovery of human induced pluripotent stem cells (iPSCs) by Shinya Yamanaka et al., they are increasingly being used in cardiovascular research for disease modelling, drug screening, personalized medicine, and regenerative medicine. Although previous studies have shown that transplantation of either human embryonic stem cell-derived cardiomyocytes (hESC-CMs) or iPSC-derived cardiomyocytes (iPSC-CMs) to non-human primates can engraft or improve cardiac function through direct cardiomyocyte replacement, there are still several hurdles to overcome, including short-term ventricular arrythmias and long-term sustainable engraftment. In this issue of the journal, El Harane et al. sought to test whether EVs secreted by iPSC-derived cardiovascular progenitors (iPSC-PGs) can recapitulate the therapeutic effects of direct transplantation of iPSC-PGs. They successfully isolated EVs from iPSC-PGs, and found that iPSC-CMs did not produce EVs althogh the mechanism is unclear. EVs were internalized in vitro to target cells, which improved cell survival and proliferation of cultured H9C2 cardiomyocytes, and promoted angiogenesis including scratch wound healing and tube formation. Similarly, in vivo EV injection improved cardiac function in a murine myocardial infarction model. Surprisingly, the injection of EVs outperformed transplantation of their parent progenitor cells. The EVs were enriched with 16 highly conserved microRNAs (miRNAs), which are associated with biological functions expected to ameliorate heart failure. In terms of target genes of the miRNAs, they showed that the hearts from the three groups treated with iPSC-CMs, iPSCPGs, and EVs showed distict gene expression patterns. The work by El Harane et al. highlights the effect of EVs secreted by iPSC-PGs on chronic heart failure following myocardial infarction. In terms of clinical application, these results have three important implications. First, the source of EVs is progenitor cells differentiated from iPSCs, which are more available than hESCs from the ethical point of view. Second, the EV therapy is considered to be relatively safe because it is a cell-free therapy. Third, EV therapy was more effective in improving cardiac function in vivo than the direct transplantation of parent stem cells. In their previous studies, Kervadec et al. showed that the injection of EVs secreted from human embryonic stem cell-derived cardiovascular progenitor cells (hESC-PGs) could provide beneficial effects equivalent to those of cell transplantation therapy of parent hESCPGs in the treatment of chronic heart failure in mice.. While EV

Bioenergetic and functional consequences of cellular therapy: activation of endogenous cardiovascular progenitor cells

Homing of intravenously infused embryonic stem cell- derived cells to injured hearts after myocardial infarction

Therapeutic angiogenesis by transplantation of human embryonic stem cell-derived CD133+ endothelial progenitor cells for cardiac repair.

Intravenous Administration of Embryonic Stem Cells Home into Injured Hearts and Improve Cardiac Function Post Myocardial Infarction in Rats

C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Stem Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function After Myocardial Infarction in a Paracrine Manner.

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

VEGF enhances functional improvement of postinfarcted hearts by transplantation of ESC-differentiated cells.

Human Embryonic Stem Cell-Derived Cardiovascular Progenitors Repair Infarcted Hearts Through Modulation of Macrophages Via Activation of Signal Transducer and Activator of Transcription 6

Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy in Mouse Permanent Ischemia and Ischemia-Reperfusion Models

hESCs‐Derived Early Vascular Cell Spheroids for Cardiac Tissue Vascular Engineering and Myocardial Infarction Treatment

Transient secretion of VEGF protein from transplanted hiPSC-CMs enhances engraftment and improves rat heart function post MI

An acute immune response underlies the benefit of cardiac stem cell therapy

Induced Pluripotent Stem Cells As a Biopharmaceutical Factory for Extracellular Vesicles

Bioenergetic And Functional Consequences Of Stem Cell-Based Vegf Delivery In Pressure-Overloaded Swine Hearts

Human endometrium-derived stem cell improves cardiac function after myocardial ischemic injury by enhancing angiogenesis and myocardial metabolism

PLURIPOTENT STEM CELL-DERIVED CARDIOVASCULAR PROGENITORS DIFFFERENTIATED ON LAMININ 221 REGENERATE AND IMPROVE FUNCTION OF INFARCTED SWINE HEARTS

Mitochondrial Membrane Potential Identifies a Subpopulation of Mesenchymal Progenitor Cells to Promote Angiogenesis and Myocardial Repair

The Effect of Controlled Expression of Vegf by Transduced Myoblasts in A Cardiac Patch on Vascularization in A Mouse Model of Myocardial Infarction

Intra-myocardial delivery of mesenchymal stem cells ameliorates left ventricular and cardiomyocyte contractile dysfunction following myocardial infarction.

Suicide gene-mediated sequencing ablation revealed the potential therapeutic mechanism of induced pluripotent stem cell-derived cardiovascular cell patch post-myocardial infarction.

Deterioration of cardiac function after acute myocardial infarction is prevented by transplantation of modified endothelial progenitor cells overexpressing endothelial NO synthases.